Pfm Health Sciences, LP Blueprint Medicines Corp Transaction History

Pfm Health Sciences, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$49.93 - $77.7 $6.51 Million - $10.1 Million	130,366 New	130,366 $8.59 Million
Q2 2019 Aug 14, 2019	SELL	$73.54 - $97.8 $70.9 Million - $94.3 Million	-964,075 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$48.7 - $86.6 $24.7 Million - $43.9 Million	-506,361 Reduced 34.44%	964,075 $77.2 Million
Q4 2018 Feb 14, 2019	BUY	$45.57 - $74.26 $1.39 Million - $2.26 Million	30,398 Added 2.11%	1,470,436 $79.3 Million
Q3 2018 Nov 13, 2018	BUY	$58.91 - $78.32 $35.1 Million - $46.7 Million	595,957 Added 70.6%	1,440,038 $112 Million
Q2 2018 Aug 14, 2018	SELL	$60.96 - $101.18 $4.51 Million - $7.48 Million	-73,909 Reduced 8.05%	844,081 $53.6 Million
Q1 2018 May 15, 2018	BUY	$73.28 - $102.95 $3.76 Million - $5.28 Million	51,250 Added 5.91%	917,990 $84.2 Million
Q4 2017 Feb 14, 2018	SELL	$62.91 - $88.32 $48 Million - $67.3 Million	-762,346 Reduced 46.8%	866,740 $65.4 Million
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $69 Million - $113 Million	1,629,086	1,629,086 $113 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

Stay updated on Pfm Health Sciences, LP with notifications on news.